Sign In
Buy BNTX
$89.59
+1.14 (+1.29%)
At Close: Jun 04, 2026
Although US stocks closed mixed on Thursday, but healthcare stocks recorded gains, gaining over 0.2% in the previous session. Biotechnology stocks were among the top performers in the sector, adding a
BioNTech SE Sponsored ADR (BNTX) Just Overtook the 20-Day Moving Average
11:17am, Tuesday, 29'th Nov 2022
Good things could be on the horizon when a stock surpasses the 20-day simple moving average. How should investors react?
7 Stocks on the Perfect 10 List
06:47pm, Wednesday, 23'rd Nov 2022
A stock that scores a perfect 10 should be on every investor's list of stocks to buy. Any company that receives full marks on quality, value, or growth are stocks I'd considering a perfect 10.
Pfizer and BioNTech updated booster shows strong results against new omicron sublineages in fresh analysis of data
10:52am, Friday, 18'th Nov 2022
A fresh analysis of data on the immune response generated by the bivalent COVID-19 booster showed strong results against the newer omicron sublineages, Pfizer and German partner BioNTech said Friday.
New Pfizer-BioNTech Covid Vaccine Is More Effective Than The Original, Study Shows
10:35am, Friday, 18'th Nov 2022
An estimated 68% of Americans are fully vaccinated.
Pfizer and BioNTech say bivalent booster increases neutralizing antibodies against new omicron variants
06:59am, Friday, 18'th Nov 2022
Pfizer Inc. PFE, +0.58% and German partner BioNTech SE BNTX, +0.82% said Friday a new analysis of data reviewing the immune response created by the omicron BA.4/BA.5 adapted bivalent COVID vaccine sho
Pfizer, BioNTech Take Next Step Toward A Pan-Covid Vaccine — But Is The Demand There?
11:07am, Thursday, 17'th Nov 2022
Pfizer and BioNTech said Thursday they've started testing a next-generation Covid shot, but the vaccine stocks tumbled. The post Pfizer, BioNTech Take Next Step Toward A Pan-Covid Vaccine — But Is T
Moderna Surges On New Omicron Data, Pulling Pfizer, BioNTech Along For The Ride
02:42pm, Monday, 14'th Nov 2022
Moderna stock popped Monday after the company said its bivalent Covid booster led to a 15-fold jump in omicron-blocking antibodies. The post Moderna Surges On New Omicron Data, Pulling Pfizer, BioNTec
Pfizer, BioNTech BA.4/BA.5-adapted booster gets CHMP recommendation for 5-11 year olds in EU
10:11am, Thursday, 10'th Nov 2022
Pfizer Inc. PFE, +1.81% and Germany-based partner BioNTech SE BNTX, -3.39% said Thursday that their booster dose of the omicron BA.4/BA.5-adapted bivalent COVID vaccine for 5-to-11 year olds was recom
This COVID-19 Vaccine Stock Has More to Offer
09:53am, Thursday, 10'th Nov 2022
The vaccine revenue was nice, but it's time to look ahead.
BioNTech SE (BNTX) Q3 2022 Earnings Call Transcript
10:45am, Monday, 07'th Nov 2022
BioNTech SE (NASDAQ:BNTX ) Q3 2022 Earnings Conference Call November 7, 2022 8:00 AM ET Company Participants Sylke Maas - Vice President, Investor Relations & Strategy Ugur Sahin - Chief Executive Off
BioNTech beats on earnings despite waning COVID vaccine demand
10:28am, Monday, 07'th Nov 2022
COVID19 Yahoo Finance's Anjalee Khemlani joins the Live show to discuss third-quarter earnings for BioNTech and news that the biotechnology company is raising the lower end of its full-year outlook fo
BioNTech Takes A Hit Despite Doubling Profit Views, Raising 2022 Outlook
09:14am, Monday, 07'th Nov 2022
BioNTech doubled third-quarter profit expectations Monday and raised its full-year outlook for Covid vaccine sales — but BNTX stock toppled. The post BioNTech Takes A Hit Despite Doubling Profit Vie
BioNTech Issues Bright Revenue Outlook. But The Stock Sinks After Profit Drop.
07:43am, Monday, 07'th Nov 2022
BioNTech said it now expects full-year Covid-vaccine revenue of €16 billion-€17 billion, from €13 billion-€17 billion previously.
BioNTech profit and revenue fall sharply from year-ago period but top estimates
06:17am, Monday, 07'th Nov 2022
BioNTech SE BNTX, +6.24% said Monday it had net income of $1.784 billion euros, or EUR6.98 a share, in the third quarter, down from EUR6.087 billion, or EUR12.35 a share, in the year-earlier period. R
